Tempest Therapeutics (TPST) Current Leases (2019 - 2026)
Tempest Therapeutics (TPST) posted Current Leases of $1.2 million for Q4 2025, up 3.92% sequentially from $1.1 million in Q3 2025, and up 37.17% YoY from $869000.0 in Q4 2024.
Tempest Therapeutics (TPST) Current Leases (2019 - 2026) Analysis & Trends
Tempest Therapeutics has reported Current Leases for 7 years, with the latest figure at $1.2 million in Q4 2025.
- Quarterly Current Leases rose 37.17% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (up 37.17% YoY) and the FY2025 annual result came in at $1.2 million, up 37.17% from the prior year.
- Current Leases advanced to $1.2 million in Q4 2025 per TPST's latest filing, from $1.1 million in the prior quarter.
- Over five years, Current Leases peaked at $1.5 million in Q2 2021 and troughed at $828000.0 in Q3 2024.
- A 5-year average of $1.2 million and a median of $1.1 million in 2023 frame the typical range for Current Leases.
- The sharpest annual moves came in 2021 and 2022: Current Leases surged 102.53% in 2021, then tumbled 38.27% in 2022.
- Over 5 years, Current Leases stood at $1.4 million in 2021, then slipped by 2.01% to $1.4 million in 2022, then tumbled by 32.63% to $952000.0 in 2023, then declined by 8.72% to $869000.0 in 2024, then surged by 37.17% to $1.2 million in 2025.
- According to Business Quant data, Current Leases over the past three periods registered $1.2 million, $1.1 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.29 Mn |
| Dec 31, 2025 | 1.19 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 869,000.00 |
| Sep 30, 2024 | 828,000.00 |
| Jun 30, 2024 | 939,000.00 |
| Mar 31, 2024 | 858,000.00 |
| Dec 31, 2023 | 952,000.00 |
| Sep 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | 1.41 Mn |
| Mar 31, 2023 | 1.33 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 871,000.00 |
| Jun 30, 2022 | 1.05 Mn |
| Mar 31, 2022 | 1.47 Mn |
| Dec 31, 2021 | 1.44 Mn |
| Sep 30, 2021 | 1.41 Mn |
| Jun 30, 2021 | 1.48 Mn |